PRTA Prothena Corporation plc

+4.87  (14%)
Previous Close 33.85
Open 40.89
Price To book 3.66
Market Cap 1492289670
Shares 38,540,539
Volume 3,266,759
Short Ratio 4.76
Av. Daily Volume 499,860

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation of dosing announced July 5, 2017.
Parkinson's disease
Phase 1b data released September 28, 2017 - insufficient meaningful clinical effect for further development.
Psoriatic Arthritis
Phase 3 trial fully enrolled - noted August 8, 2017. Final event 2H 2019.
AL Amyloidosis
Phase 2b data due 2Q 2018.
Previously-treated patients with AL amyloidosis and persistent cardiac dysfunction

Latest News

  1. Why Prothena Corp plc Shot 14.4% Higher Today
  2. Prothena Rockets On Celgene Tie-Up In Neurological Diseases
  3. Biotech Stock RoundUp: ALXN & ARNA Up on Study Data, PRTA Teams Up With Celgene
  4. Prothena Rallies on Multi-Year Collaboration With Celgene
  5. Prothena Stock Skyrockets on Celgene Collab
  6. This Biotech Stock Rocketed On A $150 Million Deal With Celgene
  7. Prothena shares surge on Celgene collaboration
  8. Prothena Announces Global Neuroscience Research & Development Collaboration with Celgene for Novel Therapies for Patients with Neurodegenerative Diseases
  9. Options Traders Expect Huge Moves in Prothena (PRTA) Stock
  10. Prothena (PRTA) Up 8.7% Since Earnings Report: Can It Continue?
  11. Research Report Identifies Prothena, UROGEN PHARMA, Mizuho Financial Group, 1-800 FLOWERS.COM, Willis Towers Watson Public, and First Connecticut with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  12. Prothena to Present a Broad Range of Scientific and Health Outcomes Data at the 16th International Symposium on Amyloidosis
  13. Prothena to Participate in the Barclays Global Healthcare Conference
  14. Edited Transcript of PRTA earnings conference call or presentation 14-Feb-18 9:30pm GMT
  15. Prothena's (PRTA) Loss Narrows in Q4, Pipeline Progresses
  16. Prothena reports 4Q loss
  17. Prothena Reports Fourth Quarter and Full Year 2017 Financial Results, and Provides Financial Guidance and R&D Update